RxDoctor Payments Data

Boon Chew, MD

Hematology & Oncology · Daytona Beach, FLNPI 1134221070

Payments from drug & device makers

$6,415in general payments, 2019–2025

Across 303 payments — averaging $21.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$887
  • Beigene, Ltd.$525
  • Genentech USA, Inc.$329
  • Amgen$311
  • AstraZeneca$307
  • Takeda Pharmaceuticals U.S.A., Inc.$302
  • plus $4K from 47 others

What the payments were for

  • Consulting fees$5258%
  • Food & beverage$5,77690%
  • Education$1142%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,415 in reported general payments places this provider in the 40th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida

Medicare billing

Part B allowed, 2024
$95,540
Medicare patients
249
Services billed
1,000

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrukinsaZanubrutinib27$401,184
Lenalidomide35$357,730
RevlimidLenalidomide19$244,598
CalquenceAcalabrutinib Maleate16$241,310
VerzenioAbemaciclib15$229,129
MekinistTrametinib Dimethyl Sulfoxide11$201,810
XtandiEnzalutamide12$167,452
EliquisApixaban103$73,951
TasignaNilotinib Hcl14$72,250
Deferasirox11$17,224
Exemestane27$5,650
Anastrozole110$1,736
Lidocaine13$972
Tamoxifen Citrate48$841
Ondansetron Hcl56$697

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisMekinist, Tasigna$887$274,06025 claims
Bristol Myers SquibbRevlimid$163$244,59819 claims
AstraZenecaCalquence$307$241,31016 claims
Lilly USA, LLCVerzenio$185$229,12915 claims
Astellas Pharma US IncXtandi$47$167,45212 claims
PfizerEliquis$255$73,951103 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 694 hematology & oncology providers in Florida.

Other hematology & oncology in Daytona Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →